BACKGROUND:Comorbid anxiety is common in depressive disorders in both middle and late life, and it affects response to antidepressant treatment. AIMS: To examine whether anxiety symptoms predict acute and maintenance (2 years) treatment response in late-life depression. METHOD: Data were drawn from a randomised double-blind study of pharmacotherapy and interpersonal psychotherapy for patients age 70 years and over with major depression. Anxiety symptoms were measured using the Brief Symptom Inventory. Survival analysis tested the effect of pre-treatment anxiety on response and recurrence. RESULTS: Patients with greater pretreatment anxiety took longer to respond to treatment and had higher rates of recurrence. Actuarial recurrence rates were 29% (pharmacotherapy, lower anxiety), 58% (pharmacotherapy, higher anxiety), 54% (placebo, lower anxiety) and 81% (placebo, higher anxiety). CONCLUSIONS: Improved identification and management of anxiety in late-life depression are needed to achieve response and stabilise recovery.
RCT Entities:
BACKGROUND: Comorbid anxiety is common in depressive disorders in both middle and late life, and it affects response to antidepressant treatment. AIMS: To examine whether anxiety symptoms predict acute and maintenance (2 years) treatment response in late-life depression. METHOD: Data were drawn from a randomised double-blind study of pharmacotherapy and interpersonal psychotherapy for patients age 70 years and over with major depression. Anxiety symptoms were measured using the Brief Symptom Inventory. Survival analysis tested the effect of pre-treatment anxiety on response and recurrence. RESULTS:Patients with greater pretreatment anxiety took longer to respond to treatment and had higher rates of recurrence. Actuarial recurrence rates were 29% (pharmacotherapy, lower anxiety), 58% (pharmacotherapy, higher anxiety), 54% (placebo, lower anxiety) and 81% (placebo, higher anxiety). CONCLUSIONS: Improved identification and management of anxiety in late-life depression are needed to achieve response and stabilise recovery.
Authors: Simon J C Davies; Benoit H Mulsant; Alastair J Flint; Anthony J Rothschild; Ellen M Whyte; Barnett S Meyers Journal: Compr Psychiatry Date: 2014-02-12 Impact factor: 3.735
Authors: Jordan F Karp; Debra K Weiner; Mary A Dew; Amy Begley; Mark D Miller; Charles F Reynolds Journal: Int J Geriatr Psychiatry Date: 2010-06 Impact factor: 3.485
Authors: Wenjun Li; Yang Wang; B Douglas Ward; Piero G Antuono; Shi-Jiang Li; Joseph S Goveas Journal: J Psychiatr Res Date: 2016-12-12 Impact factor: 4.791
Authors: Robert M Carney; Kenneth E Freedland; Brian C Steinmeyer; Eugene H Rubin; Michael W Rich Journal: J Psychosom Res Date: 2016-07-19 Impact factor: 3.006
Authors: Carmen Andreescu; Benoit H Mulsant; Patricia R Houck; Ellen M Whyte; Sati Mazumdar; Alexandre Y Dombrovski; Bruce G Pollock; Charles F Reynolds Journal: Am J Psychiatry Date: 2008-05-01 Impact factor: 18.112
Authors: Alex Cohen; Stephen E Gilman; Patricia R Houck; Katalin Szanto; Charles F Reynolds Journal: Soc Psychiatry Psychiatr Epidemiol Date: 2008-09-25 Impact factor: 4.328
Authors: Carmen Andreescu; Bea Herbeck Belnap; Bruce L Rollman; Patricia Houck; Caroline Ciliberti; Sati Mazumdar; M Katherine Shear; Eric J Lenze Journal: Am J Geriatr Psychiatry Date: 2008-10 Impact factor: 4.105
Authors: Meera Sheffrin; Henry C Driscoll; Eric J Lenze; Benoit H Mulsant; Bruce G Pollock; Mark D Miller; Meryl A Butters; Mary Amanda Dew; Charles F Reynolds Journal: J Clin Psychiatry Date: 2009-02-10 Impact factor: 4.384
Authors: Carmen Andreescu; Olusola Ajilore; Howard J Aizenstein; Kimberly Albert; Meryl A Butters; Bennett A Landman; Helmet T Karim; Robert Krafty; Warren D Taylor Journal: Am J Geriatr Psychiatry Date: 2019-08-07 Impact factor: 4.105